Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2016

01-05-2016 | Original Paper

Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting

Authors: I. Marion de Sumari-de Boer, Jossy van den Boogaard, Kennedy M. Ngowi, Hadija H. Semvua, Krisanta W. Kiwango, Rob E. Aarnoutse, Pythia T. Nieuwkerk, Gibson S. Kibiki

Published in: AIDS and Behavior | Issue 5/2016

Login to get access

Abstract

HIV infected and tuberculosis (TB) patients need high levels of treatment adherence to achieve optimal treatment outcomes. We conducted a pilot-study on real time medication monitoring (RTMM) in a resource-limited setting. We enrolled five HIV infected and five TB patients from Kilimanjaro, Tanzania. They took their medication using RTMM. When the device was not opened on time, patients received a reminder SMS. After 3 months, we interviewed patients. Six patients (60 %) reached adherence of >95 %. Nine-hundred-twenty-two of 1104 intakes (84 %) were on time. Five-hundred reminders (45 %) were sent, of which 202 (40 %) were incorrect, because of an unstable mobile network. Nine patients found the device helpful and nine mentioned it keeps medication safe. Six patients reported that the size was too big. Five patients mentioned they received incorrect reminders. The device is considered useful in Kilimanjaro. Optimization of the device should consider network connectivity and the size of the device.
Literature
1.
Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.CrossRefPubMedPubMedCentral
2.
Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97.CrossRefPubMed
3.
Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.CrossRefPubMed
4.
Ammassari A, Trotta MP, Shalev N, et al. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(4):e113–5.CrossRefPubMed
5.
Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMed
6.
Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed
7.
8.
Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.CrossRefPubMedPubMedCentral
9.
Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103–10.CrossRefPubMed
10.
Coomes CM, Lewis MA, Uhrig JD, et al. Beyond reminders: a conceptual framework for using short message service to promote prevention and improve healthcare quality and clinical outcomes for people living with HIV. AIDS Care. 2011;24(3):348–57.CrossRefPubMed
11.
da Costa TM, Barbosa BJ, Gomes e Costa DA, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81:257–69.CrossRefPubMedPubMedCentral
12.
de Boer M. Hakuna shida! The influence of costs, care, community and counseling on adherence to ARV in Kilimanjaro. 2008.
13.
de Boer M. Combination antiretroviral therapy among immigrant and indigenous HIV infected patients: quality of life and treatment adherence. Dissertation University of Amsterdam, Amsterdam. 2011.
14.
de Boer IM, Prins JM, Sprangers MA, Nieuwkerk PT. Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):635–40.CrossRefPubMed
15.
de Bruin M, Viechtbauer W, Schaalma HP, et al. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–50.CrossRefPubMed
16.
de Bruin M, Hospers HJ, van Breukelen GJ, et al. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol. 2010;29(4):421–8.CrossRefPubMed
17.
Evalan BV. Real time medication monitoring with optional smart reminding. Internet. 2014;2-2-2015.
18.
Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm. 1996;24(3):265–82.CrossRefPubMed
19.
Green J, Thorogood N. Chapter 8: Analysing qualitative data. Qualitative methods for health research. London: Sage; 2004. p. 173.
20.
21.
Haberer JE, Kwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27:2166–8.CrossRefPubMed
22.
Hettema JE, Hosseinbor S, Ingerskoll KS. Feasibility and reliability of interactive voice response assessment of HIV medication adherence: research and clinical implications. HIV Clin Trials. 2012;13(5):271–7.CrossRefPubMedPubMedCentral
23.
IAPAC. Feeling watched: emotional and moral effects of Wisepill use promote adherence for adults taking antiretroviral therapy (ART) in Rural Southwestern Uganda. Adherence 2015; A decade of success, a world of opportunities. 2015.
24.
Kelly JD, Giordano TP. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(8):1137–9.CrossRefPubMed
25.
Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials. 2009;10:87.CrossRefPubMedPubMedCentral
26.
Lester R, Mills E, Kariri A, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838–45.CrossRefPubMed
27.
Lyimo RA, van den Boogaard J, Msoka E, et al. Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. BMC Public Health. 2011;11:92.CrossRefPubMedPubMedCentral
28.
Lyimo RA, de Bruin M, van den Boogaard J, et al. Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health. 2012;12:716.CrossRefPubMedPubMedCentral
29.
Mbuagbaw L, Thabane L, Ongolo-Zogo P, et al. The Cameroon mobile phone SMS (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy. Trials. 2011;12:5.CrossRefPubMedPubMedCentral
30.
Ministry of Health and Social Welfare URoT. Manual of the National Tuberculosis and Leprosy Programme in Tanzania. 5th ed. Dar es Salaam: MoH; 2010.
31.
Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238.CrossRefPubMedPubMedCentral
32.
Nsanzimana S, Ruton H, Lowrance DW, et al. Cell phone-based and internet-based monitoring and evaluation of the national antiretroviral treatment program during rapid scale-up in Rwanda: TRACnet, 2004-2010. J Acquir Immune Defic Syndr. 2012;59(2):e17–23.CrossRefPubMed
33.
Orrell C, Cohen K, Mauff K, et al. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(3):e73–83.CrossRef
34.
Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15:1381–96.CrossRefPubMed
35.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMed
36.
Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825–34.CrossRefPubMedPubMedCentral
37.
Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.CrossRefPubMed
38.
Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet. 1992;22(3):238–46.CrossRefPubMed
39.
Sabin LL, Bachman DeSilva M, Gill CJ, et al. Improving adherence to antiretroviral therapy with triggered real-time text message reminders: the China adherence through technology study. J Acquir Immune Defic Syndr. 2015;69(5):551–9.CrossRefPubMed
40.
Shuter J, Sarlo JA, Kanmaz TJ, Rode R, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.CrossRefPubMed
41.
Siedner MJ, Lankowski A, Musinga D, et al. Optimizing network connectivity for mobile health technologies in sub-Saharan Africa. PLoS One. 2012;7(9):e45643.CrossRefPubMedPubMedCentral
42.
Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.CrossRefPubMedPubMedCentral
43.
van den Boogaard J. Non-adherence to tuberculosis treatment: an integral approach to measure and prevent it. Dissertation Radboud University, Nijmegen. 2011.
44.
van den Boogaard J, Lyimo R, Irongo CF, et al. Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.PubMed
45.
van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8.CrossRefPubMed
46.
van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89(9):632–9.CrossRefPubMedPubMedCentral
47.
van den Boogaard J, Msoka E, Homfray M, et al. An exploration of patient perceptions of adherence to tuberculosis treatment in Tanzania. Qual Health Res. 2012;22(6):835–45.CrossRefPubMed
48.
Vervloet M, van Dijk L, Santen-Reestman J, et al. Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a randomised controlled trial to evaluate the effect of monitoring patients’ medication use combined with short message service (SMS) reminders. BMC Health Serv Res. 2011;11:5.CrossRefPubMedPubMedCentral
49.
Vervloet M, van Dijk L, de Bakker DH, et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. Diabet Med. 2014;31(7):821–8.CrossRefPubMed
50.
Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.CrossRefPubMed
51.
Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res. 1999;8(3):247–62.CrossRefPubMed
52.
Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45(4):461–7.CrossRefPubMed
53.
Wilson IB, Bangsberg DR, Shen J, et al. Multisite Adherence Collaboration on HIV 14 Investigators. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64:448–54.CrossRefPubMedPubMedCentral
54.
World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: WHO; 2003.
Metadata
Title
Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting
Authors
I. Marion de Sumari-de Boer
Jossy van den Boogaard
Kennedy M. Ngowi
Hadija H. Semvua
Krisanta W. Kiwango
Rob E. Aarnoutse
Pythia T. Nieuwkerk
Gibson S. Kibiki
Publication date
01-05-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1254-0

Other articles of this Issue 5/2016

AIDS and Behavior 5/2016 Go to the issue

Original Paper

Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients?

Original Paper

Community-Based Accompaniment Mitigates Predictors of Negative Outcomes for Adults on Antiretroviral Therapy in Rural Rwanda

Original Paper

Food Insecurity, Dietary Diversity, and Body Mass Index of HIV-Infected Individuals on Antiretroviral Therapy in Rural Haiti

Original Paper

Cost-Utility Analysis of Three U.S. HIV Linkage and Re-engagement in Care Programs from Positive Charge

Original Paper

Antiretroviral Refill Adherence Correlates with, But Poorly Predicts Retention in HIV Care

Original Paper

Adherence to Antiretroviral Therapy Among Children Living with HIV in South India
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits